PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026
Summary
Hemophilia A and B are rare, recessive, X-linked genetic disorders that almost exclusively afflict males and are characterized by the failure of blood to form normal clots after damage to veins and tissue. Hemophilia A is significantly more predominant than hemophilia B. According to the Centers for Disease Control and Prevention (CDC), there are approximately 20,000 patients in the US with hemophilia, and hemophilia A is four times more common than hemophilia B.
It is estimated that the total hemophilia A and B markets in the 7MM had a value of $6.68Bn in 2016. This analysis includes the sales of desmopressin (DDVAP), plasma-derived and recombinant factor concentrates, and alternative coagulation promoters (ACPs).
Hemophilia sales are forecast to grow to $7.97bn in 2026, at a modest Compound Annual Growth Rate (CAGR) of 1.8%. The US represents the largest market in hemophilia, accounting for approximately 60% of total product sales in 2016 and 2026. The five major European markets (5EU: France, Germany, Italy, Spain, and the UK) represents the second largest market region, accounting for approximately 32% of the total product sales in 2016 and 31% in 2026.
Major drivers of the hemophilia market in the 7MM over the forecast period include –
– Increasing rates of routine prophylaxis in pediatric and adult hemophilia A and B.
– The introduction and uptake of new long-acting factors and ACPs.
Traditionally, the hemophilia market has been dominated by short-acting rFVIII or FIX concentrates. However, in recent years the hemophilia market has become increasingly competitive due to the approval of extended half-life products that can reduce the burden associated with prophylaxis. These improvements have mainly benefited hemophilia B patients, while a substantial unmet need remains for hemophilia A patients and patients with inhibitors who do not respond to standard treatments.
The report “PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026” provides overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
In particular, this report provides the following –
– Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.
– Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Amunix, Apitope, Aptevo Therapeutics, Bayer, Baxter, Baxalta, Biogen, BioMarin, Bioverativ, Catalyst Biosciences, Chugai, CSL Behring, Dimension Therapeutics, LFB, Novo Nordisk, Octapharma, Opko Biologics, Pfizer, Revo Biologics, Roche/Genentech, Sangamo Therapeutics, Shire, Spark Therapeutics, uniQure, Xenetic Biosciences.
Scope
– Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
– Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.
– Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
